Pressure to Seal Trump Trade Deals Ramps Up With Two Weeks to Go
Two weeks from President Donald Trump's self-imposed deadline to reach deals with the US's major trading partners, some of the most-watched talks aimed at clinching agreements to avoid higher tariffs are struggling to get over the finish line.
There's a lot at stake: As of July 9, exporting nations without a bilateral accord in place will face Trump's so-called 'Liberation Day' tariffs that are much higher than the current baseline 10% level applied to most countries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Hiscox partners Bellwether for wildfire insurance modelling
Hiscox has partnered Bellwether, a team at X, Alphabet's Moonshot Factory, to introduce a new approach to wildfire modelling for the Californian insurance market. The collaboration involves Hiscox London Market's Property division working with Bellwether to incorporate its AI-powered wildfire model into existing risk scoring and modelling processes, seeking to improve risk selection and pricing for insurance products. The new model is already providing additional insurance options for homeowners in California. Bellwether's tool analyses extensive data to estimate wildfire risk, incorporating historical environmental information and various risk drivers. The company claims that Bellwether has been designed to forecast wildfire risk up to five years ahead. It will enable Hiscox to offer sustainable insurance solutions tailored to the evolving risk landscape. The model generates absolute wildfire risk scores, providing transparency regarding the factors contributing to each score. Hiscox London market's property divisional director James Brady stated: 'This partnership allows us to integrate the very latest AI-powered modelling from Bellwether, with other third-party models and our own advanced risk modelling framework. 'It's a powerful combination that can support a much more sustainable insurance solution for Californian homeowners. With this world-class, multi-model approach, we can quantify an insured's exposure to wildfire risk with more precision, which in turn enables us to offer Hiscox capacity to a wider range of customers.' Sarah Russell from Bellwether added: 'Bellwether leverages the best of Google's geospatial knowledge and AI technology to help companies and communities adapt better to the changing landscape of severe weather events like wildfire. We are excited to be working with Hiscox to show how Bellwether can help provide additional measurement, analysis and predictions for this dynamic risk and, in turn, assist in the availability and sustainable provision of wildfire insurance for Californian homeowners.' "Hiscox partners Bellwether for wildfire insurance modelling" was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Axios
22 minutes ago
- Axios
Trump declares victory as Iran, Israel acknowledge shaky ceasefire
The Trump-brokered ceasefire between Iran and Israel has, for now, brought an abrupt and extraordinary end to one of the Middle East's most explosive confrontations in decades. Why it matters: The 12-day war sent shockwaves through a region already reeling from nearly two years of historic volatility and violence, beginning with Hamas' Oct. 7 terrorist attack on Israel. President Trump's military intervention to destroy Iranian nuclear sites brought the U.S. to the precipice of a major conflict that four of his predecessors had sought to avoid. But it also set the stage for a ceasefire that — if it holds — could usher in a fundamentally new era for the Middle East, its security and its dominant powers. State of play: Israel is accusing Iran of breaking the ceasefire. For several hours before the ceasefire came into effect — and for several minutes after — Iran fired missile barrages at Israel that killed civilians, threatening to upend Trump's deal. After Trump announced on social media at 6:02pm ET that Israel and Iran had agreed to a "Complete and Total CEASEFIRE." Iranian state TV eventually said the ceasefire was in effect. Around 2am ET, Israeli Prime Minister Benjamin Netanyahu confirmed Israel agreed to a ceasefire with Iran in coordination with Trump. Behind the scenes: Trump's efforts to end the war began in earnest on Saturday, shortly after U.S. B-2 bombers launched 14 massive bunker-buster bombs that almost completely destroyed Iran's three main nuclear facilities. The president instructed envoy Steve Witkoff to communicate to the Iranians his desire to negotiate a deal to end the war, according to a White House official. Iran initially refused to engage and said diplomacy would be possible only after it exacted revenge by striking U.S. targets, a source with direct knowledge said. But prior to launching Monday's missile attack on the Al-Udeid Air Base in Qatar, Iran sent messages to the U.S. — via Qatar — conveying when and what targets they intended to strike, a White House official said. Immediately after the strike, which left no casualties, the Iranians sent another back-channel message notifying the White House that they would not conduct any further attacks on U.S. targets. The White House responded — again via the Qataris — saying the U.S. would not retaliate to the Iranian attack and reiterating its readiness to resume negotiations. On Monday evening, when it became clear the Iranian strike on Al-Udeid was over, Trump called Israeli Prime Minister Benjamin Netanyahu and told him he wanted the war to end, the White House official said. Netanyahu agreed to the ceasefire and said Israel would not conduct any more strikes as long as Iran stopped launching missiles, the White House official said. Trump spoke with the emir of Qatar and Vice President Vance spoke with the Qatari prime minister, who then relayed the message to Iran and finalized the terms of the ceasefire — including the time it would begin. When it was all agreed, Trump announced the ceasefire in a post on Truth Social with his signature bombast. "I would like to congratulate both Countries, Israel and Iran, on having the Stamina, Courage, and Intelligence to end, what should be called, "THE 12 DAY WAR." Trump wrote Monday evening. "This is a War that could have gone on for years, and destroyed the entire Middle East, but it didn't, and never will! God bless Israel, God bless Iran, God bless the Middle East, God bless the United States of America, and GOD BLESS THE WORLD!" The big picture: The surprise war Israel launched against Iran on June 13 dealt a final blow to the so-called "Axis of Resistance," a network of Iranian-backed groups that have long targeted U.S. and Israeli interests throughout the region. As a direct and indirect result of Israeli action, Hamas' military capabilities were decimated, Hezbollah was significantly degraded, the Assad regime in Syria collapsed, and pro-Iranian militias in Iraq were effectively deterred. Iran's Supreme Leader, Ayatollah Ali Khamenei — still believed to be hiding in a bunker — now faces the loss of his top military leadership, the near-total destruction of his nuclear program, the deaths of key nuclear scientists, the elimination of half his ballistic missile force, and the near-collapse of his air defenses. Zoom in: The war ended with Iran at its weakest point since its devastating eight-year war with Iraq in the 1980s. Israeli and U.S. officials both claim that it will take Iran years to rebuild its military power, reestablish its proxy network and restore its deterrence. Iran's nuclear program, meanwhile, has likely been set back by years — and now faces the threat of further U.S. and Israeli military action if the regime seeks to rebuild it. Between the lines: A White House official argued that it was the U.S. strike on Iran's nuclear facilities that ultimately created the conditions for ending the war. "The Iranians understood Trump wasn't playing games and the Israelis were grateful that Trump did something they couldn't do on their own — and couldn't say no when he asked them to stop," the White House official said. The official said the Iranians wanted to end the war because "they couldn't take it anymore" — and that the U.S. is confident Iran's nuclear facilities and enriched uranium stockpile have been destroyed. "They don't have any ability to build a nuclear weapon now," the White House official claimed. The bottom line: Trump's achievement is especially significant because the U.S. appears to have avoided a prolonged war in the Middle East — a scenario he feared and his MAGA supporters loathed.
Yahoo
22 minutes ago
- Yahoo
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
Company to host webcast and conference call on June 24, 2025 at 8:00am ET CAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Tuesday, June 24, 2025 at 8:00 a.m. ET, to discuss pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer from the global ARROS-1 Phase 1/2 clinical trial. Webcast and Conference Call Information To access the call, please dial +1 (800) 836-8184 (domestic) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined to the Nuvalent call. Accompanying slides and a live video webcast will be available in the Investors section of the Nuvalent website at A replay and accompanying slides will be archived on the Nuvalent website for 30 days. About Zidesamtinib and the ARROS-1 Phase 1/2 Clinical Trial Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with treatment-emergent ROS1 mutations such as G2032R. In addition, zidesamtinib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with dual TRK/ROS1 inhibitors and to drive deep, durable responses for patients across all lines of therapy. Zidesamtinib has received breakthrough therapy designation for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with 2 or more ROS1 tyrosine kinase inhibitors and orphan drug designation for ROS1-positive NSCLC. Zidesamtinib is currently being investigated in the ARROS-1 trial (NCT05118789), a first-in-human Phase 1/2 clinical trial for patients with advanced ROS1-positive NSCLC and other solid tumors. The completed Phase 1 portion enrolled ROS1-positive NSCLC patients who previously received at least one ROS1 TKI, or patients with other ROS1-positive solid tumors who had been previously treated. The Phase 1 portion of the trial was designed to evaluate the overall safety and tolerability of zidesamtinib, with additional objectives including determination of the recommended Phase 2 dose, characterization of the pharmacokinetic profile, and evaluation of preliminary anti-tumor activity. The ongoing global, single arm, open label Phase 2 portion is designed with registrational intent for TKI-naïve and TKI pre-treated patients with ROS1-positive NSCLC. About Nuvalent Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the expected timing of data announcements; the clinical development program for zidesamtinib; the design and enrollment of Nuvalent's clinical trials, including for ARROS-1 its intended pivotal registration-directed design the potential of Nuvalent's pipeline programs, including zidesamtinib; Nuvalent's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: risks that Nuvalent may not fully enroll its clinical trials or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that preliminary results of clinical trials may not be predictive of future results from the same or other trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from our clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1 trial; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements. View original content to download multimedia: SOURCE Nuvalent, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
